Investors in Fulgent Genetics Under Scrutiny as Pomerantz Law Firm Conducts Investigation

Introduction

On March 12, 2026, Pomerantz LLP, a leading law firm specializing in securities class action litigation, announced that it is investigating claims on behalf of investors associated with Fulgent Genetics, Inc. (NASDAQ: FLGT). This investigation arises in the context of serious allegations that may indicate unlawful business practices or securities fraud involving particular officers and directors at Fulgent.

Background Information on Fulgent Genetics

Fulgent Genetics, a biotech company known for its advanced genetic testing solutions, has been under the market’s microscope following a press release on February 27, 2026. In this release, the company reported its financial performance for the fourth quarter and the entirety of 2025, but what caught the attention of investors was its lower-than-expected guidance for 2026. The announcement highlighted that one of its greatest clients had transitioned a substantial portion of its business operations in-house, which significantly impacted Fulgent’s anticipated earnings.

This revelation played a crucial role in a staggering decline in the company’s stock price, which plummeted by $9.43 per share—a reduction amounting to 38.09%—bringing the closing price down to $15.33 on the day the press release was issued.

Legal Concerns and Pomerantz’s Role

Given the drastic drop in Fulgent’s stock price and the circumstances surrounding its financial disclosures, investor concern surged, prompting Pomerantz LLP to step in. The firm is urging affected investors to come forward, particularly those who may have suffered financial losses tied to the stock’s decline.

Pomerantz LLP has a long-standing reputation for successfully advocating for victims of securities fraud and has a rich history of class action litigation dating back over 85 years. Founded by Abraham L. Pomerantz, often considered the “dean of the class action bar”, the firm has fought diligently for investors’ rights against corporate misconduct and has recovered significant damages for its clients in multiple cases. Now, they are prepared to leverage that expertise in representing Fulgent Genetics shareholders.

Call to Action for Investors

Investors who feel they have been negatively impacted by Fulgent’s recent financial disclosures and subsequent stock price collapse are encouraged to reach out to Pomerantz LLP. They can contact Danielle Peyton at [email protected] or via phone at 646-581-9980, extension 7980. This investigation may lead to a class-action lawsuit designed to protect the rights of investors and hold accountable any parties engaged in fraudulent practices. Investors can also find more information about joining the class action on the firm’s website.

Conclusion

As the investigation unfolds, shareholders of Fulgent Genetics should remain vigilant and stay informed about developments that may impact their investments. Pomerantz LLP is committed to uncovering the truth and ensuring investors receive fair treatment in the wake of any potential wrongdoing. The outcome of this investigation could set precedents for legal accountability within the biotech sector and affect many investors who placed their trust and capital in Fulgent Genetics.

Fulgent’s stock has raised pivotal questions regarding corporate ethics and accountability, making this case crucial not just for the firm's investors but for the broader financial landscape as well. All affected parties are advised to stay proactive and consider legal recourse with a firm that has a proven track record in safeguarding the rights of investors.